Investigation of selenium, intracellular selenium and selenoprotein P status in patients with inflammatory rheumatic diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031779

Enrollment

300

Registered

2023-05-09

Start date

2022-07-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Group 1: Patients with inflammatory rheumatic diseases The following are recorded: laboratory-chemical selenium status, scores: DAS28, CDAI, SDAI, FfbH Group 2: Patients with osteoarthritis The follow

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: one of the above-mentioned diagnoses from the group of inflammatory rheumatic diseases: rheumatoid arthritis; psoriatic arthritis; juvenile idiopathic arthritis; osteoarthritis Patient consent

Exclusion criteria

Exclusion criteria: pregnancy, therapy with glucocorticoids >10mg prednisolone equivalent/day for >2 weeks, post organ transplantation, substitution with selenium.

Design outcomes

Primary

Measure	Time frame
Selenium status assessment in patients with inflammatory rheumatic diseases: Measurement of selenoprotein P by ELISA	—

Secondary

Measure	Time frame
Correlation of disease activity of the underlying disease (DAS28) with selenium/selenoproteinP.	—

Countries

Germany

Contacts

Public ContactPaula Hoff

MVZ Endokrinologikum Berlin am Gendarmenmarkt

paula.hoff@amedes-group.com+49302091562290

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026